Abstract
: With the development of global industrialization, urbanization and changes of people’s lifestyle, Diabetes Mellitus, DM has become a serious worldwide health issue. The prevalence of diabetes in China is more than 10%. Due to the huge population base, China has surpassed the U.S. and India, becoming the country with the largest diabetic population in the world. Diabetic retinopathy (DR) is one of the most common complications of DM. The latest epidemiological survey shows that 17.8–29.2% of China’s diabetes patients developed DR, and it has become the leading cause of blindness in adults over the age of 40. Despite the continued emergence of new medicine and treatment in the past ten years, and a large number of global clinical trials have been carried out, we still couldn’t prevent the occurrence and development of DR. Microvascular damage caused by DM has been a top priority in the prevention and treatment of diabetic complications. Chinese government attaches great importance to the prevention and treatment of DR and has included it into China’s plan of the prevention and treatment of blindness. In this presentation, I’m going to focus on the pathogenesis of DR, especially the relationship between immune inflammatory response and DR. Major challenges and solutions in clinical treatment were discussed as well.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
